Just hours before it was to face the start of a trial, Sun Pharmaceuticals of India said it will pay $485 million to settle years-old lawsuits alleging its Ranbaxy Pharmaceuticals subsidiary falsified data to hoodwink the FDA into granting exclusive approvals for its generic drugs, thus delaying competition and making people pay exorbitant prices for the generics.
Source: Drug Industry Daily